Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering
Peter S Chang1, Yi-Chun Chen1, Wei-Kai Hua1
1GenomeFrontier Therapeutics TW Co., Ltd., Taipei City, Taiwan (R.O.C.).
Plos One
|August 27, 2024
Summary
A new virus-free system efficiently produces dual-targeted CAR T-stem memory cells for treating B-cell cancers. This method enhances CAR T-cell persistence and tumor eradication, potentially improving patient outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Engineering
Background:
- CD19-targeted chimeric antigen receptor (CAR) T cell therapies revolutionized B-cell malignancy treatment.
- Challenges include antigen escape, low CAR T-cell persistence, and manufacturing difficulties.
- Current viral vector-based CAR T-cell production is complex and costly.
Purpose of the Study:
- To develop a virus-free cell-engineering system for multiplex CAR T-cell therapies.
- To demonstrate the efficient production of functional CD20/CD19 dual-targeted CAR T-stem memory (CAR-TSCM) cells.
- To evaluate the in vitro and in vivo efficacy and safety of qPB™-manufactured CAR-TSCM cells.
Main Methods:
- Utilized the Quantum pBac™ (qPB™) piggyBac transposon-based vector for virus-free CAR T-cell engineering.
- Developed CD20/CD19 dual-targeted CAR-TSCM cells.
- Assessed cell expansion, tumor eradication in vitro and in vivo, and safety using an iCasp9 suicide gene system.
Main Results:
- Achieved efficient, consistent, and robust production of functional CAR-TSCM cells using the qPB™ system.
- Demonstrated rapid tumor eradication in vivo by qPB™-manufactured CAR-T cells.
- Confirmed safe control of CAR-T cells via an iCasp9 suicide gene-inducing drug.
Conclusions:
- The qPB™ system offers a simple, efficient method for manufacturing multiplex CAR-T cells.
- This virus-free approach has the potential to improve CAR T-cell therapy efficacy.
- The technology may broaden the accessibility of advanced CAR T-cell therapies for cancer patients.
